TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05524792

Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study

Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study

Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study
Study: NCT05524792

Intervention type: OTHER
Intervention: no interventional study
Description: no interventional study
Study: NCT03113188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP501
Description: CBP501, CDDP plus Nivolumab
Study: NCT01554397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT 45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
Study: NCT04157582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: 1. Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~2. Pilates mat training performed in 5 different positions (30 minutes).~   1. One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~  2. Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~  3. Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~  4. Half roll back, Oblique roll up were performed in the sitting position.~  5. Swimming was performed in the kneeling position.~3. The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 1. Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~2. Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~3. Balance training (Wobble board training) :~   * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~  * Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times).
Study: NCT00112385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
Study: NCT03733782

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modular enteral protein - Prosource
Description: Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
Study: NCT05075473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental stabilization
Description: Physiotherapist will perform activation of multifidus in prone position. It also includes activation of transverse abdominas in crook lying position, in sitting as well as in point kneeling position to re-establish simultaneous contraction of deep muscles synergy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalized Lumber stabilization exercsies
Description: It can by performed by patient him or her self under physiotherapist's assistance. Lumber neutral position is maintained. Bridging in prone as well as supine position will be maintained.
Study: NCT04021563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR419
Description: Ascending single and multiple doses of SR419 orally
Study: NCT02595437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Study: NCT02578537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
Study: NCT01832298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitecan Hydrochloride for Injection
Description: Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
Study: NCT00310843

Intervention type: DRUG
Intervention: Nevirapine
Description: Patients with HIV-1 infection who have taken or are currently taking nevirapine
Study: NCT04245605

Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: Coronary angiogram performed either in hospital or post-discharge, within 14 days after initial hospital presentation with heart failure
Study: NCT01380132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anal injection of Nasha Dx
Description: Submucous injection of Nasha Dx 5-10 mm above dentate line
Study: NCT04021563

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single and multiple doses of placebo orally
Study: NCT06710769

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian tissue removal will be performed laparoscopically
Description: under general anesthesia concomitantly with another scheduled procedure if possible. Following removal, ovarian tissue will be shipped to University of Pittsburg Medical Center, Magee-Womens Research Institute for processing. Freezing and storing techniques will be in accordance with FDA regulations for reproductive tissues, guidelines of the American Association of Tissues Banks and any other applicable federal, state and local regulations. The tissue will be carefully separated dividing the cortex from the medulla. The cortex will then be cryopreserved for long term storage. The medulla will be shipped overnight back to the PCH Department of Pathology for histological evaluation. If pathology finds evidence of cancer in the ovarian tissue provided, they may request that all of the patient's tissue be returned to pathology for a more detailed examination, which may eliminate the tissue available for the patient's future use.
Study: NCT03223805

Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory Distress Symptom Intervention
Description: The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Distress Symptom Intervention
Description: The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required
Study: NCT03333889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Enamic hybrid crown
Description: hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emax hybrid crown
Description: high srength glass ceramic that can be milled in sections up to 1mm .
Study: NCT03258229

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Angelica gigas N. extract
Description: capsules(2cap/d, 1,000mg/d) for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 weeks
Study: NCT01251211

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin type A
Description: BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
Study: NCT00397046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study: NCT02931227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temperature obtained by the non-invasive method of zero-heat flux

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temperature obtained by the non-invasive method of zero-heat flux

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temperature obtained by the non-invasive method of zero-heat flux

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temperature obtained by the non-invasive method of zero-heat flux

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracerebral temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracerebral temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracerebral temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracerebral temperature

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arterial temperature
Study: NCT04059822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow and deep breathing
Description: Please see arm description
Study: NCT00532415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Injectable Suspension
Description: Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
Study: NCT04487821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey Exercises
Description: Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing
Study: NCT02414841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonapanitase
Study: NCT06745856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Subconjunctival, peroperative, application of 50mg/ml concentration of 5-fluoruracil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subconjunctival, peroperative application of normal saline (NaCl 0.9%)
Study: NCT03709953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg，po，QD； 28 days every cycle
Study: NCT02414841

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02943096

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CocoaVia
Description: Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill).
Study: NCT06678763

Intervention type: PROCEDURE
Intervention: CRS-HIPEC
Description: Patients with uterine leiomyosarcoma who received unprotected morcellation were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with docetaxel and gemcitabine.
Study: NCT03439085

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
Description: Given IM and via electroporation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study: NCT03105193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Saline bolus and infusion
Description: Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP Saline bolus and infusion
Description: Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Study: NCT01273558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg capsule taken orally (by mouth) on Days Days 1-8
Study: NCT02897284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness 8 weeks
Description: 8 sessions of mindfulness
Study: NCT03105193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV lignocaine bolus and infusion
Description: Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP Lignocaine bolus and infusion
Description: Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Study: NCT04440358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate BBBD
Description: BBB opening via Exablate Neuro Type 2 system to deliver carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
Study: NCT04003441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
Study: NCT02232945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of oseltamivir phosphate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of oseltamivir phosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banlangen (Radix Isatidis) granules
Study: NCT02897284

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness 2 weeks
Description: 2 sessions of mindfulness
Study: NCT03661554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T Cells
Description: The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
Study: NCT03275103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
Study: NCT02365688

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initial bolus pre-incision
Description: Measured hemodynamic response to pre-incision bolus
Study: NCT02683798

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Continuous energy restriction
Description: 1 x formula food (202-209kcal) meal replacement per day
Study: NCT02232945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of Banlangen(Radix Isatidis) granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of Banlangen(Radix Isatidis) granules
Study: NCT02893163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHANGE Intervention
Description: Canadian Health Advanced by Nutrition and Graded Exercise Protocol
Study: NCT02683798

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction
Description: 4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
Study: NCT03008213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant and Palonosetron
Description: 300 mg of netupitant and 0.5 mg of palonosetron
Study: NCT03418363

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHEA Oral Capsule
Description: Daily 100mg DHEA supplement
Study: NCT03275103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as premedication during Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as premedication during Cycle 1.
Study: NCT04794179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Naida Link CROS
Description: Individuals 18+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
Study: NCT02893163

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care by Family Doctor